China long-acting bronchodilator market is anticipated to grow at a substantial rate of 3.8% during the forecast period. High level of air pollution and the significant number of smokers in China is boosting the demand for long-acting bronchodilators in the country. Additionally, the rising geriatric population susceptible to asthma and COPD within the country is also driving the demand for bronchodilators. From June 2012 to May 2015, a survey was conducted by the Ministry of Health and Ministry of Science and Technology of China. About 51,000 citizens participated in the survey with 21,500 men and 29,500 women, according to which, it was estimated that about 100 million adults in 2015 had the problem of COPD in the country. The prevalence is higher in men as compared to women. As per the estimation, there were 68.4 million men and 31.5 million women affected by COPD. 

Request a Free Sample of our Report on China Long-Acting Bronchodilator Market: https://www.omrglobal.com/request-sample/china-long-acting-bronchodilator-market

China long-acting bronchodilator market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, nasal, parenteral, and inhalation. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the increasing pool of aging population susceptible to the high prevalence of asthma in the country.

A full Report of Germany China Long-Acting Bronchodilator Market is Available at: https://www.omrglobal.com/industry-reports/china-long-acting-bronchodilator-market

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing long-acting bronchodilator to cater to a wide range of customers within and outside the country. The major players of the China long-acting bronchodilator market include Cipla Ltd., AstraZeneca PLC, Beximo Pharmaceuticals Ltd., GlaxoSmithKline PLC, Novartis AG, Teva Pharmaceuticals Industries Ltd., and Teijin Pharma Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players. For instance, in July 2019, Cipla Ltd. announced joint-venture (JV) with China-based Jiangsu Acebright Pharma to make respiratory drugs in China. This JV will allow Cipla to expand its footprints in the country and further strengthen its revenue stream.

Market Segmentation

China Long-Acting Bronchodilator Market by Route of Administration 

• Oral
• Nasal
• Parenteral
• Inhalation

China Long-Acting Bronchodilator Market by Application

• Asthma 
• Chronic Obstructive Pulmonary Disease (COPD)
• China Long-Acting Bronchodilator Market by End-User
• Homecare
• Hospitals and Clinics

Company Profiles

• Adamis Pharmaceuticals Corp.
• AstraZeneca PLC
• Beximo Pharmaceuticals Ltd.
• Boehringer Ingelheim International GmbH
• Cipla Ltd.
• GlaxoSmithKline PLC
• Novartis AG
• ResMed Corp.
• Pulmatrix Inc.
• Sunovion Pharmaceuticals
• Teijin Pharma Ltd.
• Teva Pharmaceuticals Industries Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/china-long-acting-bronchodilator-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com 
Contact no: +1 646-755-7667, +91 780-304-0404